Outer membrane vesicle vaccine to prevent B. parapertussis and B. pertussis infection

DANIELA BOTTERO; EMILIA GAILLARD; ORMAZABAL MAXIMILIAN; ERREA AGUSTINA; GRISELDA MORENO; M RUMBO; DANIELA HOZBOR

Conferencia; XIV World Congress on Pertussis; 2013

The number of cases caused by Bordetella parapertussis, has risen sustained in the last years. The widely used cellular (wP) or acellular (aP) pertussis vaccines have little or no efficacy against B. parapertussis. In an effort to devise an effective acellular vaccine against B. parapertussis infection, outer membrane vesicles (OMVs) were obtained from B. parapertussis. Proteomic analysis of the resulting OMVs, designated OMVsBpp, evidenced the presence of more than 20 different protein antigens in the formulation, including several surface immunogens such as pertactin. The characterized OMVsBpp were used in murine B. parapertussis intranasal challenge model to examine their protective capacity when administered by systemic route. Immunized BALB/c mice were challenged with sublethal doses of B. parapertussis. Significant differences between immunized animals and the negative control group were observed (p < 0.001). OMVsBpp protected against B. parapertussis infection, whereas current commercial aP vaccine showed little protection against such pathogen. More interestingly, protection induced by OMVsBpp against B. pertussis was comparable to our previously designed vaccine consisting in OMVs derived from B. pertussis (OMVsBp). For these experiments we used as a positive control the current commercial aP in high dose. As expected aP offered protection against B. pertussis in mice. The protective capacity of OMVsBpp against both Bordetella species was unaltered when formulated with tetanus and diphtheria toxoids. Altogether the results presented here showed that the OMVs from B. parapertussis are an attractive vaccine candidate to protect against whooping cough induced by B. parapertussis but also by B. pertussis.